

STATEMENT SHOWING PRILIMINARY TECHNICAL EVALUATION FOR T NO 178 (GENERAL MEDICINES)					
S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
1	9M INDIA LIMITED	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for products mentioned at S No's 5, 12, 13, 24, 25, 28, 29, 35 after submission of product approvals. & May be considered for products at S No 3, 8, 10, 15, 17, 22, 24, 27, 31, 34, 35 after submission of consent required supply of requiremen pack size The firm may be considered after submission of latest CA certificate			
	1	737	Amlodipine Tablets IP 5mg		May be considered
	2	37	Atenolol Tablets IP 50mg		May be considered
	3	73	Benzyl Benzoate application IP 25%w/w, 450ml bottole	Pack size not available considered after submission of consent supply with required pack size	May not be considered
	4	58	Bisacodyl Tablets IP 5 mg(Enteric Coated)		May be considered
	5	53	Bupivacaine Hcl Injection IP 0.5 Percentage , in 20ml vial	Not submitted product approval May be considered after submission of product approval	May not be considered
	6	1123	Cetirizine Hcl Tablets IP 10mg		May be considered
	7	94	Ciprofloxacin Tablets IP 500 mg		May be considered
	8	2245	Clindamycin Injection 150 mg/ml in 2ml ampoule	Not mentioned pack size May be considered after taking consent for 2ml amp supply	May not be considered
	9	412375	Dextromethorphan oral Syrup 60 ml		May be considered
	10	198	Diclofenac Sodium Injection IP25 mg / ml in 3ml ampoule	Not mentioned pack size May be considered after taking consent for 3ml amp supply	May not be considered
	11	1137	Domperidone Tablets IP 10 mg		May be considered
	12	209	Dopamine Hcl Injection IP 200mg in 5ml vial and ampoule	Not submitted product approval May be considered after submission of product approval	May not be considered
	13	422084.01	Ferric Carboxy Maltose Injection 500mg in 10ml vial	Not submitted product approval May be considered after submission of product approval	May not be considered
	14	1629	Fluconazole Tablets IP 200mg		May be considered
	15	743	Furazolidone Suspension IP 25mg/5ml,60ml	Not mentioned pack size May be considered after taking consent for supply of 60ml	May not be considered
	16	264.01	Furazolidone Tablets IP 100 mg		May be considered
	17	294.01	Gentamicin Injection IP 40 mg / ml in 2ml Vial	Not mentioned pack size May be considered after taking consent for 2ml amp supply	May not be considered
	18	299.01	Glibenclamide Tablet 2.5 mg		May be considered
	19	299	Glibenclamide Tablet 5 mg		May be considered
	20	4231	Hysocine butyl bromide Tablet 10mg		May be considered
	21	140224049	Inj. Multivitamin 10ml		May be considered
	22	608	Iron Sucrose Injection BP 100 mg / 5ml Ampoule/Vial	The approval submitted is of different than that of required May be considered after submission of product approval	May not be considered
	23	1637	Lactulose Solution 3.325gm/5ml in 100ml bottle		May be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	24	1310	Methyl Prednesolone Sodium Succinate Injection USP 500 mg	Not submitted product approval with required specification May be considered after submission of product approval	May not be considered
	25	1880	Metoprolol Succinate Tablets IP 25 mg	Not submitted for conventional tablet forms submitted for "SR" May be considered after submisison for conventional form	May not be considered
	26	2351	Naproxen Sodium Tablet 500mg		May be considered
	27	1892	Neomycin Skin Ointment 0.5% w/v 30gm	Not mentioned pack size May be considered after taking consent for supply of 30gm	May not be considered
	28	2367	Oint.Salicylic Acid IP 6.0% w/w 30 grms tube	Not submitted product approval May be considered after submission of product approval	May not be considered
	29	2414	S. Metoprolol PR Tablet 25mg	Not submitted product approval May be considered after submission of product approval	May not be considered
	30	1682	Salicylic Acid Cream 5% , 30gms tube		May be considered
	31	140224061	Silver Sulphadiazine (Nano Crystalline) Cream 0.5%W/W, 20 GM tube	Not mentioned pack size May be considered after taking consent for supply of 20gm	May not be considered
	32	412374	Sodium chloride nasal Drops 20ml	Not mentioned pack size May be considered after taking consent for supply of 20ml	May not be considered
	33	2429	Spirolonactone Tablets IP 50 mg		May be considered
	34	2432	Thiamine Injection 100mg / ml vial 2 ml	Not mentioned pack size May be considered after taking consent for supply of 2ml	May not be considered
	35	2440	Zinc Sulphate Dispersible Tablet10mg	Not submitted product approval May be considered after submission of product approval	May not be considered
2	ABARIS HEALTHCARE PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for all the quoted items			
	1	162	Compound Sodium Lactate Injection IP 500ml BFS / FFS		May be considered
	2	229	Dextrose Injection IP 5%w/v in 500ml BFS / FFS		May be considered
	3	224	Dextrose with Sodium Chloride Injection 5% + 0.9% IP in 500ml IV BFS / FFS		May be considered
	4	640	Sodium Chloride Injection IP 0.9%in 500ml BFS / FFS		May be considered
3	Abbott Healthcare Private Limited	Technical Evaluation Remarks by Committee of DCA: May be considered for products at S No 1 & 2 after submission of copies of product approvals with latest Retention period. May be considere after submission of EMD fee your firm was Blacklisted by Tamil Nadu Medical Services Corporation (TNMSC), Hence your are requested to submit further Clarification/Explanation on this order.			
	1	37	Atenolol Tablets IP 50mg	Not submitted the Retention copy of product approval May be considered after submission of Retention	May not be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	2	2088	Febuxostat Tab 40mg	Not submitted the Retention copy of product approval May be considered after submission of Retention	May not be considered
4	ABBOTT INDIA LIMITED	Technical Evaluation Remarks by Committee of DCA: Firm may be considered			
	1	1637	Lactulose Solution 3.325gm/5ml in 100ml bottle		May be considered
5	Able Pharma	Technical Evaluation Remarks by Committee of DCA: May be considered for products at S No 2, 3 and for S No 4 after submission of consent for supply is requested pack size and for product S No 1 after submission of product approval			
	1	1623	Chloramphenicol Ear drops IP 5ml	Not submitted product approval May be considered after submission of product approval	May not be considered
	2	2457	Natamycin Eye Drops 5%w/v		May be considered
	3	412374	Sodium chloride nasal Drops 20ml		May be considered
	4	2478	Sodium Cromoglycate 2 percentage Eye Drops 5ml	Not mentioned pack size May be considered after taking consent for supply of 5ml pack	May not be considered
6	Adroit Pharmaceuticals Pvt Limited	Technical Evaluation Remarks by Committee of DCA: The firm may be considered for all products except item code: 1137 The item 1137 - May be considered after submission of product approval for required specification			
	1	737	Amlodipine Tablets IP 5mg		May be considered
	2	37	Atenolol Tablets IP 50mg		May be considered
	3	1453	B Complex therapeutic (NFI III)		May be considered
	4	73	Benzyl Benzoate application IP 25%w/w, 450ml bottole		May be considered
	5	1123	Cetirizine Hcl Tablets IP 10mg		May be considered
	6	1137	Domperidone Tablets IP 10 mg	The specification required is film coated, where license mentioned as Each tablet containg without specifying coating May be considered after submission of product approval for required specification	May not be considered
	7	264.01	Furazolidone Tablets IP 100 mg		May be considered
	8	647	Silver Sulphadiazine Cream USP 1%W/W, 100gms tube		May be considered
7	Akums Drugs & pharmaceuticals Limited	Technical Evaluation Remarks by Committee of DCA: May be considered for products at S No 8, 9, 10, 11. May be considered for the remaining products after submitting the Retention copies of product approvals			

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	1	737	Amlodipine Tablets IP 5mg	Not submitted the Retained product approval May be considered after submission of Retention	May not be considered
	2	37	Atenolol Tablets IP 50mg	Not submitted the Retained product approval May be considered after submission of Retention	May not be considered
	3	58	Bisacodyl Tablets IP 5 mg(Enteric Coated)	Not submitted the Retained product approval May be considered after submission of Retention	May not be considered
	4	1123	Cetirizine Hcl Tablets IP 10mg	Not submitted the Retained product approval May be considered after submission of Retention	May not be considered
	5	94	Ciprofloxacin Tablets IP 500 mg	Not submitted the Retained product approval May be considered after submission of Retention	May not be considered
	6	1137	Domperidone Tablets IP 10 mg	Not submitted the Retained product approval May be considered after submission of Retention	May not be considered
	7	299	Glibenclamide Tablet 5 mg	Not submitted the Retained product approval May be considered after submission of Retention	May not be considered
	8	608	Iron Sucrose Injection BP 100 mg / 5ml Ampoule/Vial		May be considered
	9	1639	Mannitol 20% I.V. Infusion IP 100ml bottle BFS/FFS		May be considered
	10	2351	Naproxen Sodium Tablet 500mg		May be considered
	11	2119	Paracetamol Solution for Infusion (10mg/ml) in 100ml glass bottle i.e.1gm/100ml BFS/FFS		May be considered
8	ALAPATI PHARMA	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for both quoted items			
	1	1341	Amoxycillin 250mg +125mg Clavulanic Acid Tablets		May be considered
	2	1621	Cefixime Dispersible Tablets USP 100 mg		May be considered
9	alkem laboratories ltd	Technical Evaluation Remarks by Committee of DCA: The firm may be considered for all products except item code: 1341 The item 1137 - May be considered after submission of product approval for required strength			
	1	1341	Amoxycillin 250mg +125mg Clavulanic Acid Tablets	The approval furnished by firm contained name of product in "Tablets" and composition as "Suspension" May be considered after submission of approval for required strength	May not be considered
	2	1621	Cefixime Dispersible Tablets USP 100 mg		May be considered
	3	2236	Cefixime Oral Suspension 25mg/ml, 10ml Bottle		May be considered
	4	1123	Cetirizine Hcl Tablets IP 10mg		May be considered
	5	94	Ciprofloxacin Tablets IP 500 mg		May be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	6	1639	Mannitol 20% I.V. Infusion IP 100ml bottle BFS/FFS		May be considered
	7	2119	Paracetamol Solution for Infusion (10mg/ml) in 100ml glass bottle i.e.1gm/100ml BFS/FFS		May be considered
10	Appasamy Ocular Devices (P) Ltd.	Technical Evaluation Remarks by Committee of DCA: Firm may be considered quoted item			
	1	2478	Sodium Cromoglycate 2 percentage Eye Drops 5ml		May be considered
11	BACTOLAC FORMULATIONS PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: The firm may be considered for products at S No's 1, 2 & 3 only. For product at S No 4 after submission of product approval for the release specified			
	1	1123	Cetirizine Hcl Tablets IP 10mg		May be considered
	2	94	Ciprofloxacin Tablets IP 500 mg		May be considered
	3	2088	Febuxostat Tab 40mg		May be considered
	4	2414	S. Metoprolol PR Tablet 25mg	Not submitted the required release approval May be considered after submission of proper product approval	May not be considered
12	Bajaj Healthcare Limited	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for product at S No 2 and for product at S No 1 after submission of taking consent for supply in requested pack size			
	1	422084.01	Ferric Carboxy Maltose Injection 500mg in 10ml vial	May be considered after taking consent for 10ml supply	May not be considered
	2	4231	Hysocine butyl bromide Tablet 10mg		May be considered
13	Bharat Serums And Vaccines Ltd	Technical Evaluation Remarks by Committee of DCA: Firm may be considered quoted item			
	1	1413	Anti-D Immunoglobulin (Human) Injection 300mcg 2ml vial		May be considered
	2	1681	Rabies Antiserum Injection Immunoglobulin, Equine 300 IU/ml		May be considered
14	Biocon Biologics Limited	Technical Evaluation Remarks by Committee of DCA: The firm may be considered for item 1631, The firm may not be considered for item 1634 on only loan license furnished by the firm			
	1	1631	Human Premixed Insulin Injection IP 30/70 in 10 ml vial	The firm valid loan license of M/s Eris Bioux Pvt Ltd, MP and submitted valid mfg license	May be considered
	2	1634	Insulin Injection (Soluble) Human Injection IP 40 IU / ml in 10 ml vial	Not submitted product license (Primary/loan license mfg permitted only for human premixed insulin inj 30/70)	May not be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
15	CADILA PHARMACEUTICALS LIMITED	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for the products at S No's 1, 2, 3, 4 & 7. For products at S .No 8 after obtaining consent for supply in required pack size. May be considered for products at S No's 5 & 6 after submission of valid product approvals			
	1	737	Amlodipine Tablets IP 5mg		May be considered
	2	6	Amoxicillin Capsules IP 250 mg		May be considered
	3	94	Ciprofloxacin Tablets IP 500 mg		May be considered
	4	1137	Domperidone Tablets IP 10 mg		May be considered
	5	1631	Human Premixed Insulin Injection IP 30/70 in 10 ml vial	Not submitted product approval May be considered after submission of product approval	May not be considered
	6	1634	Insulin Injection (Soluble) Human Injection IP 40 IU / ml in 10 ml vial	Not submitted product approval May be considered after submission of product approval	May not be considered
	7	608	Iron Sucrose Injection BP 100 mg / 5ml Ampoule/Vial		May be considered
	8	1637	Lactulose Solution 3.325gm/5ml in 100ml bottle	Not mentioned pack size May be considered after taking consent for supply of 100ml	May not be considered
16	CAPTAB FORMULATIONS	Technical Evaluation Remarks by Committee of DCA: The firm may be considered for all items except 1137. The item 1137 - May be considered after submission of approval for required specification			
	1	737	Amlodipine Tablets IP 5mg		May be considered
	2	37	Atenolol Tablets IP 50mg		May be considered
	3	1123	Cetirizine Hcl Tablets IP 10mg		May be considered
	4	94	Ciprofloxacin Tablets IP 500 mg		May be considered
	5	1137	Domperidone Tablets IP 10 mg	The required specification is film coated where as the firm licensed for uncoated May be considered after submission of approval for required specification	May not be considered
	6	1629	Fluconazole Tablets IP 200mg		May be considered
	7	299	Glibenclamide Tablet 5 mg		May be considered
17	CENTURION REMEDIES PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: The firm may be considered for all items except 1137. The item 1137 - May be considered after submission of approval for required specification			
	1	737	Amlodipine Tablets IP 5mg		May be considered
	2	1341	Amoxycillin 250mg +125mg Clavulanic Acid Tablets		May be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	3	37	Atenolol Tablets IP 50mg		May be considered
	4	1621	Cefixime Dispersible Tablets USP 100 mg		May be considered
	5	94	Ciprofloxacin Tablets IP 500 mg		May be considered
	6	412375	Dextromethorphan oral Syrup 60 ml		May be considered
	7	1137	Domperidone Tablets IP 10 mg	The license furnished approval for uncoated tablet, where as required specification is film coated May be considered after submission of approval for required specification	May not be considered
	8	1629	Fluconazole Tablets IP 200mg		May be considered
	9	299.01	Glibenclamide Tablet 2.5 mg		May be considered
	10	299	Glibenclamide Tablet 5 mg		May be considered
	11	4231	Hysocine butyl bromide Tablet 10mg		May be considered
	12	2351	Naproxen Sodium Tablet 500mg		May be considered
	13	497	Nifedipine Capsules IP 10mg		May be considered
	14	647	Silver Sulphadiazine Cream USP 1%W/W, 100gms tube		May be considered
	15	2429	Spironolactone Tablets IP 50 mg		May be considered
18	CIPCO LIMITED	Technical Evaluation Remarks by Committee of DCA: Firm may be considered quoted items			
	1	737	Amlodipine Tablets IP 5mg		May be considered
	2	37	Atenolol Tablets IP 50mg		May be considered
	3	1453	B Complex therapeutic (NFI III)		May be considered
	4	1123	Cetirizine Hcl Tablets IP 10mg		May be considered
	5	94	Ciprofloxacin Tablets IP 500 mg		May be considered
	6	412375	Dextromethorphan oral Syrup 60 ml		May be considered
	7	264.01	Furazolidone Tablets IP 100 mg		May be considered
	8	1637	Lactulose Solution 3.325gm/5ml in 100ml bottle		May be considered
	9	1370	Vitamin A Paediatric retinol solution 100000 IU per ml		May be considered
	10	2440	Zinc Sulphate Dispersible Tablet10mg		May be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
19	CIPLA LTD	Technical Evaluation Remarks by Committee of DCA: Firm may be considered quoted items May be considered after submission of Original Annexure-II (Submitted xerox copy)			
	1	737	Amlodipine Tablets IP 5mg		May be considered
	2	1629	Fluconazole Tablets IP 200mg		May be considered
	3	1880	Metoprolol Succinate Tablets IP 25 mg		May be considered
	4	2414	S. Metoprolol PR Tablet 25mg		May be considered
	5	1656	Salbutamol Nebulising solution IP 10ml		May be considered
20	CMG BIOTECH PVT LTD	Technical Evaluation Remarks by Committee of DCA: Firm may be considered quoted items			
	1	737	Amlodipine Tablets IP 5mg		May be considered
	2	37	Atenolol Tablets IP 50mg		May be considered
	3	1123	Cetirizine Hcl Tablets IP 10mg		May be considered
	4	94	Ciprofloxacin Tablets IP 500 mg		May be considered
	5	2088	Febuxostat Tab 40mg		May be considered
	6	1811	Fluvoxamine Tablets 50mg		May be considered
	7	2339	Mebeverine Hydrochloride IP 135mg Tablet		May be considered
	8	2429	Spirolactone Tablets IP 50 mg		May be considered
21	COPMED PHARMACEUTICALS PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: The firm may be considered for the above said product after submission of valid Retention copy of product approval			
	1	1341	Amoxycillin 250mg +125mg Clavulanic Acid Tablets	Not submitted the Retention copy of product approval May be considered after submission of Retention	May not be considered
22	COTEC HEALTHCARE LIMITED	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for item 1629 The firm may be considered for remaining products after submission of valid product approvals			
	1	6	Amoxicillin Capsules IP 250 mg	The firm failed to furnish valid product license May be considered after submission of valid product approval	May not be considered
	2	1123	Cetirizine Hcl Tablets IP 10mg	The firm failed to furnish valid product license May be considered after submission of valid product approval	May not be considered
	3	94	Ciprofloxacin Tablets IP 500 mg	The firm failed to furnish valid product license May be considered after submission of valid product approval	May not be considered
	4	1629	Fluconazole Tablets IP 200mg		May be considered
	5	1656	Salbutamol Nebulising solution IP 10ml	The firm failed to furnish valid product license May be considered after submission of valid product approval	May not be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	6	412374	Sodium chloride nasal Drops 20ml	The firm failed to furnish valid product license May be considered after submission of valid product approval	May not be considered
	7	2440	Zinc Sulphate Dispersible Tablet10mg	The firm failed to furnish valid product license May be considered after submission of valid product approval	May not be considered
23	Cyano Pharma Private Limited	Technical Evaluation Remarks by Committee of DCA: (1) The firm may be considered for items 37, 73, 1123, 94, 1629, 264.01, 4231, 2367, 574 and 2440, 1453 (2) The firm may not be considered for 737 and 1637			
	1	737	Amlodipine Tablets IP 5mg	Not submitted mfg license	May not be considered
	2	37	Atenolol Tablets IP 50mg		May be considered
	3	1453	B Complex therapeutic (NFI III)		May be considered
	4	73	Benzyl Benzoate application IP 25%w/w, 450ml bottle		May be considered
	5	1123	Cetirizine Hcl Tablets IP 10mg		May be considered
	6	94	Ciprofloxacin Tablets IP 500 mg		May be considered
	7	1629	Fluconazole Tablets IP 200mg		May be considered
	8	264.01	Furazolidone Tablets IP 100 mg		May be considered
	9	4231	Hysocine butyl bromide Tablet 10mg		May be considered
	10	1637	Lactulose Solution 3.325gm/5ml in 100ml bottle	Strength of approved product is not matched with the required strength	May not be considered
	11	2367	Oint.Salicylic Acid IP 6.0% w/w 30 grms tube		May be considered
	12	574	Pyridoxine Hcl Tablets IP 5 mg		May be considered
	13	2440	Zinc Sulphate Dispersible Tablet10mg		May be considered
24	D.J.Laboratories PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: (1) The firm had not submitted NCC which is not older than 12 months of date of tender. Hence, the firm may be considered for products 162, 229, 224, 140224018 and 640 after submission of valid NCC. (2) The firm may be considered for products 1150, 1639 and 2119 after submission of valid product approvals and valid NCC			
	1	162	Compound Sodium Lactate Injection IP 500ml BFS / FFS		May be considered
	2	1150	Dextrose Injection IP 25%w/v in 100ml BFS / FFS	Not produced valid product license May be considered after submission of valid product license	May not be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	3	229	Dextrose Injection IP 5%w/v in 500ml BFS / FFS		May be considered
	4	224	Dextrose with Sodium Chloride Injection 5% + 0.9% IP in 500ml IV BFS / FFS		May be considered
	5	140224018	Inj Sodium chloride 0.9%100ml		May be considered
	6	1639	Mannitol 20% I.V. Infusion IP 100ml bottle BFS/FFS	Not produced valid product license May be considered after submission of valid product license	May not be considered
	7	2119	Paracetamol Solution for Infusion (10mg/ml) in 100ml glass bottle i.e.1gm/100ml BFS/FFS	Not produced valid product license May be considered after submission of valid product license	May not be considered
	8	640	Sodium Chloride Injection IP 0.9%in 500ml BFS / FFS		May be considered
25	ESKAG PHARMA PVT LTD	Technical Evaluation Remarks by Committee of DCA: Firm may be considered quoted item			
	1	422084.01	Ferric Carboxy Maltose Injection 500mg in 10ml vial		May be considered
26	Eurokem Laboratories Pvt Ltd	Technical Evaluation Remarks by Committee of DCA: The firm not submitted valid product approvals. Hence, the products may be considered after submission of valid product license. Further, the firm held approval for Vitamin B Complex (Therapeutic) NFI only but not for NFI III`			
	1	37	Atenolol Tablets IP 50mg	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered
	2	1453	B Complex therapeutic (NFI III)	Firm held approval for NFI only, but not NFI III	May not be considered
	3	58	Bisacodyl Tablets IP 5 mg(Enteric Coated)	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered
	4	1123	Cetirizine Hcl Tablets IP 10mg	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered
	5	94	Ciprofloxacin Tablets IP 500 mg	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered
	6	264.01	Furazolidone Tablets IP 100 mg	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered
	7	299.01	Glibenclamide Tablet 2.5 mg	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	8	299	Glibenclamide Tablet 5 mg	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered
27	FARISTA VANIJYA PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: The firm is issued STOP PRODUCTION ORDER vide memo no. DCSG/70/2024-25 dated 24/02/2025. Hence the products S.No. 1 to 8 May not be considered and also failed to produce valid NCC			
	1	162	Compound Sodium Lactate Injection IP 500ml BFS / FFS		May not be considered
	2	229	Dextrose Injection IP 5%w/v in 500ml BFS / FFS		May not be considered
	3	224	Dextrose with Sodium Chloride Injection 5% + 0.9% IP in 500ml IV BFS / FFS		May not be considered
	4	140224018	Inj Sodium chloride 0.9%100ml		May not be considered
	5	1437	Isolyte-M Injection		May not be considered
	6	1639	Mannitol 20% I.V. Infusion IP 100ml bottle BFS/FFS		May not be considered
	7	2119	Paracetamol Solution for Infusion (10mg/ml) in 100ml glass bottle i.e.1gm/100ml BFS/FFS		May not be considered
	8	640	Sodium Chloride Injection IP 0.9%in 500ml BFS / FFS		May not be considered
28	FERRING PHARMACEUTICALS PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: The product may be considered after submission of valid product licene controlled release pessary contain "Dinoprostin 10mg"			
	1	25082023	Dinoprostin Pessaries 10mg	May be considered after submission of valid product license with controlled release pessary contains Dinoprostin 10mg	May not be considered
29	FRESENIUS KABI INDIA PVT LTD	Technical Evaluation Remarks by Committee of DCA: Firm may be considered quoted item			
	1	2119	Paracetamol Solution for Infusion (10mg/ml) in 100ml glass bottle i.e.1gm/100ml BFS/FFS		May be considered
30	Genetek Lifesciences Pvt Ltd	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for products S No 4 and products S No 1, 2, 3, 5, 6 and 7 - may be considered after submission of valid product approval May be considered after submission of Original Annexure-II (Submitted xerox copy)			
	1	198	Diclofenac Sodium Injection IP25 mg / ml in 3ml ampoule	Not submitted valid product approval (valid upto 03-02-18) May be considered after submission of valid product approval	May not be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	2	422084.01	Ferric Carboxy Maltose Injection 500mg in 10ml vial	Not submitted valid product approval (valid upto 03-02-23) May be considered after submission of valid product approval	May not be considered
	3	294.01	Gentamicin Injection IP 40 mg / ml in 2ml Vial	Not submitted valid product approval (valid upto 03-02-23) May be considered after submission of valid product approval	May not be considered
	4	140224021	Inj Carbetocin 100 mcg/ml		May be considered
	5	608	Iron Sucrose Injection BP 100 mg / 5ml Ampoule/Vial	Not submitted valid product approval (valid upto 03-02-18) May be considered after submission of valid product approval	May not be considered
	6	140224106	Oral contrast Sodium diatrizoate 25 percentage 30ml/100ml	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered
	7	655	Water for Injection IP 10 ml amp	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered
31	GLATRIX BIOTECH PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: Firm may be considered quoted items			
	1	6	Amoxicillin Capsules IP 250 mg		May be considered
	2	1621	Cefixime Dispersible Tablets USP 100 mg		May be considered
	3	1123	Cetirizine Hcl Tablets IP 10mg		May be considered
	4	94	Ciprofloxacin Tablets IP 500 mg		May be considered
32	Grifols India Healthcare Pvt Ltd	Technical Evaluation Remarks by Committee of DCA: Firm may be considered quoted item			
	1	1367	Human Albumin Solution I.P. 20% in bottle or bag		May be considered
33	HEALERS LAB	Technical Evaluation Remarks by Committee of DCA: Firm may be considered quoted items			
	1	737	Amlodipine Tablets IP 5mg		May be considered
	2	37	Atenolol Tablets IP 50mg		May be considered
	3	1123	Cetirizine Hcl Tablets IP 10mg		May be considered
	4	94	Ciprofloxacin Tablets IP 500 mg		May be considered
	5	264.01	Furazolidone Tablets IP 100 mg		May be considered
	6	2351	Naproxen Sodium Tablet 500mg		May be considered
34	Himalaya Meditek Pvt. Ltd.	Technical Evaluation Remarks by Committee of DCA: Firm may be considered after submission of valid product approvals			
	1	737	Amlodipine Tablets IP 5mg	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	2	6	Amoxicillin Capsules IP 250 mg	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered
	3	1621	Cefixime Dispersible Tablets USP 100 mg	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered
	4	2245	Clindamycin Injection 150 mg/ml in 2ml ampoule	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered
	5	198	Diclofenac Sodium Injection IP25 mg / ml in 3ml ampoule	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered
	6	294.01	Gentamicin Injection IP 40 mg / ml in 2ml Vial	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered
	7	299.01	Glibenclamide Tablet 2.5 mg	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered
	8	299	Glibenclamide Tablet 5 mg	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered
	9	608	Iron Sucrose Injection BP 100 mg / 5ml Ampoule/Vial	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered
	10	140224042	Inj Methyl Prednisolone 40mg/ml,2m1 Amp	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered
	11	1310	Methyl Prednesolone Sodium Succinate Injection USP 500 mg	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered
	12	574	Pyridoxine Hcl Tablets IP 5 mg	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered
	13	2432	Thiamine Injection 100mg / ml vial 2 ml	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered
35	HINDUSTAN LABORATORIES LIMITED	Technical Evaluation Remarks by Committee of DCA: Firm may be considered after submission of valid product approvals			
	1	737	Amlodipine Tablets IP 5mg	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered
	2	1453	B Complex therapeutic (NFI III)	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	3	73	Benzyl Benzoate application IP 25%w/w, 450ml bottole	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered
	4	94	Ciprofloxacin Tablets IP 500 mg	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered
	5	1137	Domperidone Tablets IP 10 mg	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered
	6	1637	Lactulose Solution 3.325gm/5ml in 100ml bottle	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered
	7	1370	Vitamin A Paediatric retinol solution 100000 IU per ml	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered
36	HINDUSTAN POLYFAB	Technical Evaluation Remarks by Committee of DCA: The firm not submitted valid GMP certificate and not produced valid product mfg license for the all applied products S No 1 to 11. Hence my be considered after submission of shortfall documents mentioned above May be considered after submission of Original Annexure-II (Submitted xerox copy)			
	1	162	Compound Sodium Lactate Injection IP 500ml BFS / FFS	Not produced valid product mfg license	May not be considered
	2	1150	Dextrose Injection IP 25%w/v in 100ml BFS / FFS	Not produced valid product mfg license	May not be considered
	3	229	Dextrose Injection IP 5%w/v in 500ml BFS / FFS	Not produced valid product mfg license	May not be considered
	4	224	Dextrose with Sodium Chloride Injection 5% + 0.9% IP in 500ml IV BFS / FFS	Not produced valid product mfg license	May not be considered
	5	140224018	Inj Sodium chloride 0.9%100ml	Not produced valid product mfg license	May not be considered
	6	1437	Isolyte-M Injection	Not produced valid product mfg license	May not be considered
	7	1639	Mannitol 20% I.V. Infusion IP 100ml bottle BFS/FFS	Not produced valid product mfg license	May not be considered
	8	2119	Paracetamol Solution for Infusion (10mg/ml) in 100ml glass bottle i.e.1gm/100ml BFS/FFS	Not produced valid product mfg license	May not be considered
	9	640	Sodium Chloride Injection IP 0.9%in 500ml BFS / FFS	Not produced valid product mfg license	May not be considered
	10	24021201	Sodium Chloride Solution for Irrigation 0.9%-5Ltr	Not produced valid product mfg license	May not be considered
	11	655	Water for Injection IP 10 ml amp	Not produced valid product mfg license	May not be considered
37	INTAS PHARMACEUTICALS LTD.	Technical Evaluation Remarks by Committee of DCA: Firm may be considered after submission of valid product approvals			

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	1	1367	Human Albumin Solution I.P. 20% in bottle or bag		May not be considered
38	Ipca Laboratories Limited	Technical Evaluation Remarks by Committee of DCA: Firm may be considered quoted item your firm was Blacklisted by Assam Medical Services Corporation, Hence your are requested to submit further Clarification/Explanation on this order.			
	1	2441	Zolpidem tablets 10mg		May be considered
39	KERALA STATE DRUGS AND PHARMACEUTICALS LIMITED	Technical Evaluation Remarks by Committee of DCA: Firm may be considered after submission of valid product approval			
	1	6	Amoxicillin Capsules IP 250 mg	Submitted product approval dated 29-05-25, not submitted product approval during the period from 2020-25 which may be considered as the license given validity certificate	May not be considered
40	KONIS PHARMACEUTICALS	Technical Evaluation Remarks by Committee of DCA: Firm may be considered quoted items			
	1	198	Diclofenac Sodium Injection IP25 mg / ml in 3ml ampoule		May be considered
	2	294.01	Gentamicin Injection IP 40 mg / ml in 2ml Vial		May be considered
41	KRISHNA PHARMA	Technical Evaluation Remarks by Committee of DCA: Firm may be considered after submission of approval for pack size of 450ml			
	1	73	Benzyl Benzoate application IP 25%w/w, 450ml bottole	Pack size not matched with the requirement May be considered after submission of valid approval for required packsize	May not be considered
42	Maan Pharmaceuticals Limited	Technical Evaluation Remarks by Committee of DCA: Firm may be considered quoted items			
	1	6	Amoxicillin Capsules IP 250 mg		May be considered
	2	1341	Amoxycillin 250mg +125mg Clavulanic Acid Tablets		May be considered
	3	1621	Cefixime Dispersible Tablets USP 100 mg		May be considered
	4	422084.01	Ferric Carboxy Maltose Injection 500mg in 10ml vial		May be considered
43	MACLEODS PHARMACEUTICALS LTD	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for products S No 1 to 4, Product S No 5 may be considered after submission of valid product approval			
	1	1341	Amoxycillin 250mg +125mg Clavulanic Acid Tablets		May be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	2	1621	Cefixime Dispersible Tablets USP 100 mg		May be considered
	3	2088	Febuxostat Tab 40mg		May be considered
	4	140224059	Tab.Racecadotril 100mg		May be considered
	5	1970	Tranexamic acid Tablets BP 250mg	Not submitted valid product approval May be considered after submission of valid product approval	May not be considered
44	MACSUR PHARMAA INDIA PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: Firm may be considered quoted item			
	1	1811	Fluvoxamine Tablets 50mg		May be considered
45	MALIK LIFESCIENCES PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: Firm may be considered quoted items			
	1	6	Amoxicillin Capsules IP 250 mg		May be considered
	2	1341	Amoxycillin 250mg +125mg Clavulanic Acid Tablets		May be considered
	3	1621	Cefixime Dispersible Tablets USP 100 mg		May be considered
46	Mankind Pharma Limited	Technical Evaluation Remarks by Committee of DCA: Firm may be considered quoted items			
	1	737	Amlodipine Tablets IP 5mg		May be considered
	2	1629	Fluconazole Tablets IP 200mg		May be considered
47	MARC LABORATORIES LTD	Technical Evaluation Remarks by Committee of DCA: The firm applied all products i.e., 1, 2, 3, 4 (Subject to supply in 3ml ampoule), 5, 6, 7 may be considered			
	1	6	Amoxicillin Capsules IP 250 mg		May be considered
	2	1341	Amoxycillin 250mg +125mg Clavulanic Acid Tablets		May be considered
	3	1621	Cefixime Dispersible Tablets USP 100 mg		May be considered
	4	198	Diclofenac Sodium Injection IP25 mg / ml in 3ml ampoule		May be considered
	5	294.01	Gentamicin Injection IP 40 mg / ml in 2ml Vial		May be considered
	6	608	Iron Sucrose Injection BP 100 mg / 5ml Ampoule/Vial		May be considered
	7	1637	Lactulose Solution 3.325gm/5ml in 100ml bottle		May be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
48	MASCOT HEALTH SERIES PVT LTD	Technical Evaluation Remarks by Committee of DCA: Firm may be considered quoted items			
	1	737	Amlodipine Tablets IP 5mg		May be considered
	2	1629	Fluconazole Tablets IP 200mg		May be considered
	3	1637	Lactulose Solution 3.325gm/5ml in 100ml bottle		May be considered
	4	1880	Metoprolol Succinate Tablets IP 25 mg		May be considered
	5	2351	Naproxen Sodium Tablet 500mg		May be considered
	6	2414	S. Metoprolol PR Tablet 25mg		May be considered
	7	2441	Zolpidem tablets 10mg		May be considered
49	medopharm	Technical Evaluation Remarks by Committee of DCA: Firm may be considered quoted items			
	1	94	Ciprofloxacin Tablets IP 500 mg		May be considered
	2	4231	Hysocine butyl bromide Tablet 10mg		May be considered
50	MEDOPHARM PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: The applied item may be considered after submission of valid product mfg license by the firm			
	1	1341	Amoxycillin 250mg +125mg Clavulanic Acid Tablets	Not submitted valid product mfg license (submitted product license is valid upto 16/03/2021)	May not be considered
51	MERIL ENDO SURGERY PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: The firm applied item may be considered after submission of valid GMP certificate by the firm as the product approval is in Form-28			
	1	140224037	Tab.Levonorgestrel releasing intrauterine 52mg	Submitted product approval license in Form 28	May not be considered
52	MICRON PHARMACEUTICALS	Technical Evaluation Remarks by Committee of DCA: Firm may be considered quoted items			
	1	737	Amlodipine Tablets IP 5mg		May be considered
	2	6	Amoxicillin Capsules IP 250 mg		May be considered
	3	73	Benzyl Benzoate application IP 25%w/w, 450ml bottle		May be considered
	4	94	Ciprofloxacin Tablets IP 500 mg		May be considered
	5	412375	Dextromethorphan oral Syrup 60 ml		May be considered
	6	1137	Domperidone Tablets IP 10 mg		May be considered
	7	1629	Fluconazole Tablets IP 200mg		May be considered
	8	743	Furazolidone Suspension IP 25mg/5ml,60ml		May be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	9	264.01	Furazolidone Tablets IP 100 mg		May be considered
	10	299.01	Glibenclamide Tablet 2.5 mg		May be considered
	11	299	Glibenclamide Tablet 5 mg		May be considered
	12	1892	Neomycin Skin Ointment 0.5% w/v 30gm		May be considered
	13	2429	Spironolactone Tablets IP 50 mg		May be considered
53	MITRA INDUSTRIES PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: Firm may be considered quoted items			
	1	6630	CAPD (Continous Ambulatory Peritoneal Dialysis) Solution Set 1.5 Percentage , 2 Litres Bag With Integrated Asymmetric Y.Set		May be considered
	2	6631	CAPD (Continous Ambulatory Peritoneal Dialysis) Solution Set 2.5 Percentage , 2 Litres Bag With Integrated Asymmetric Y.Set		May be considered
	3	6632	CAPD (Continuous Ambulatory Peritoneal Dialysis) Solution Set 4.25%, 2 Litres Bag With Integrated Asymmetric Y. Set		May be considered
54	Modern Laboratories	Technical Evaluation Remarks by Committee of DCA: Firm may be considered quoted items your firm was Blacklisted by Tamil Nadu Medical Services Corporation (TNMSC), Hence your are requested to submit further Clarification/Explanation on this order.			
	1	737	Amlodipine Tablets IP 5mg		May be considered
	2	6	Amoxicillin Capsules IP 250 mg		May be considered
	3	1341	Amoxycillin 250mg +125mg Clavulanic Acid Tablets		May be considered
	4	37	Atenolol Tablets IP 50mg		May be considered
	5	2236	Cefixime Oral Suspension 25mg/ml, 10ml Bottle	Subjected to supply in 10ml bottle	May be considered
	6	94	Ciprofloxacin Tablets IP 500 mg		May be considered
	7	2245	Clindamycin Injection 150 mg/ml in 2ml ampoule		May be considered
	8	198	Diclofenac Sodium Injection IP25 mg / ml in 3ml ampoule	Subjected to supply in 3ml ampoule	May be considered
	9	1629	Fluconazole Tablets IP 200mg		May be considered
	10	743	Furazolidone Suspension IP 25mg/5ml,60ml	Subjected to supply in 60ml pack size	May be considered
	11	264.01	Furazolidone Tablets IP 100 mg		May be considered
	12	294.01	Gentamicin Injection IP 40 mg / ml in 2ml Vial		May be considered
	13	608	Iron Sucrose Injection BP 100 mg / 5ml Ampoule/Vial		May be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	14	2351	Naproxen Sodium Tablet 500mg		May be considered
	15	2432	Thiamine Injection 100mg / ml vial 2 ml		May be considered
	16	2440	Zinc Sulphate Dispersible Tablet10mg		May be considered
55	NEOCELL BIO-TECHNOLOGIES PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: Firm may be considered quoted items			
	1	1123	Cetirizine Hcl Tablets IP 10mg		May be considered
	2	94	Ciprofloxacin Tablets IP 500 mg		May be considered
56	NESTOR PHARMACEUTICALS LIMITED	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for all the quoted items			
	1	737	Amlodipine Tablets IP 5mg		May be considered
	2	6	Amoxicillin Capsules IP 250 mg		May be considered
	3	1341	Amoxycillin 250mg +125mg Clavulanic Acid Tablets		May be considered
	4	37	Atenolol Tablets IP 50mg		May be considered
	5	1621	Cefixime Dispersible Tablets USP 100 mg		May be considered
	6	1123	Cetirizine Hcl Tablets IP 10mg		May be considered
	7	94	Ciprofloxacin Tablets IP 500 mg		May be considered
	8	1137	Domperidone Tablets IP 10 mg		May be considered
	9	299	Glibenclamide Tablet 5 mg		May be considered
57	NOVO NORDISK INDIA PVT LTD	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for all the quoted items			
	1	4404	Inj Extended Half Life factor (long acting) VIII 1000 IU vial		May be considered
	2	4403	Inj Extended Half Life factor (long acting) VIII 500 IU vial		May be considered
	3	4405	Inj Extended Half Life factor IX (long acting) 500 IU vial		May be considered
	4	140224004	Inj.Basal Insulin Analogues 300 IU/ml		May be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
58	PACE BIO TECH	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for all the quoted items			
	1	2245	Clindamycin Injection 150 mg/ml in 2ml ampoule		May be considered
	2	209	Dopamine Hcl Injection IP 200mg in 5ml vial and ampoule		May be considered
	3	608	Iron Sucrose Injection BP 100 mg / 5ml Ampoule/Vial		May be considered
	4	1310	Methyl Prednesolone Sodium Succinate Injection USP 500 mg		May be considered
	5	2432	Thiamine Injection 100mg / ml vial 2 ml		May be considered
59	Paviour Pharmaceuticals Pvt. Ltd.	Technical Evaluation Remarks by Committee of DCA: The applied item may be considered after clarification obtained from the firm regarding the product licensed with individual Immunoglobulin with reference to the tender product specifications			
	1	2309	IgM enriched Immunoglobulin IgM 12 Percentage , IgG 76 Percentage and IgA 12 Percentage concentrate 10ml	The firm submitted import license for the applied product in Form-10 (S No. 10) and as per IP specification which is different from the tender specifications May be considered after clarification obtained from the firm regarding individual immunoglbulin concentration	May not be considered
60	PLASMAGEN BIOSCIENCES PVT LTD	Technical Evaluation Remarks by Committee of DCA: The firm may be considered after submission of valid Non Conviction Certificate of firm issued by licensing authority			
	1	1367	Human Albumin Solution I.P. 20% in bottle or bag	Submitted valid drug license	May not be considered
61	Polestar Power Industries	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for all the quoted items			
	1	1341	Amoxycillin 250mg +125mg Clavulanic Acid Tablets		May be considered
	2	1621	Cefixime Dispersible Tablets USP 100 mg		May be considered
62	PROMEA THERAPEUTICS PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for all the quoted items			
	1	162	Compound Sodium Lactate Injection IP 500ml BFS / FFS		May be considered
	2	1150	Dextrose Injection IP 25%w/v in 100ml BFS / FFS		May be considered
	3	229	Dextrose Injection IP 5%w/v in 500ml BFS / FFS		May be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	4	224	Dextrose with Sodium Chloride Injection 5% + 0.9% IP in 500ml IV BFS / FFS		May be considered
	5	140224018	Inj Sodium chloride 0.9%100ml		May be considered
	6	2119	Paracetamol Solution for Infusion (10mg/ml) in 100ml glass bottle i.e.1gm/100ml BFS/FFS		May be considered
	7	640	Sodium Chloride Injection IP 0.9%in 500ml BFS / FFS		May be considered
63	PUNISKA INJECTABLES PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for all the quoted items			
	1	162	Compound Sodium Lactate Injection IP 500ml BFS / FFS		May be considered
	2	229	Dextrose Injection IP 5%w/v in 500ml BFS / FFS		May be considered
	3	224	Dextrose with Sodium Chloride Injection 5% + 0.9% IP in 500ml IV BFS / FFS		May be considered
	4	140224018	Inj Sodium chloride 0.9%100ml		May be considered
	5	2119	Paracetamol Solution for Infusion (10mg/ml) in 100ml glass bottle i.e.1gm/100ml BFS/FFS		May be considered
	6	640	Sodium Chloride Injection IP 0.9%in 500ml BFS / FFS		May be considered
64	QUASAR LABS PVT. LTD.	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for all the quoted items May be considered after submission of Original Annexure-II (Submitted xerox copy)			
	1	2351	Naproxen Sodium Tablet 500mg		May be considered
	2	2414	S. Metoprolol PR Tablet 25mg		May be considered
65	Regent Ajanta Biotech	Technical Evaluation Remarks by Committee of DCA: All the products may be considered after submission of valid GMP/WHO-GMP certificate of the firm			
	1	737	Amlodipine Tablets IP 5mg	Submitted valid product license in Form-25	May be considered
	2	6	Amoxicillin Capsules IP 250 mg	Submitted valid product license in Form-28	May be considered
	3	37	Atenolol Tablets IP 50mg	Submitted valid product license in Form-25	May be considered
	4	1621	Cefixime Dispersible Tablets USP 100 mg	Submitted valid product license in Form-28	May be considered
	5	1123	Cetirizine Hcl Tablets IP 10mg	Submitted valid product license in Form-25	May be considered
	6	1629	Fluconazole Tablets IP 200mg	Submitted valid product license in Form-25	May be considered
	7	1880	Metoprolol Succinate Tablets IP 25 mg	Submitted valid product license in Form-25 & 28	May be considered
	8	2351	Naproxen Sodium Tablet 500mg	Submitted valid product license in Form-25	May be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
66	Reliance life sciences pvt ltd	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for quoted item			
	1	1367	Human Albumin Solution I.P. 20% in bottle or bag		May be considered
67	REVAT LABORATORIES PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: As per the request of the firm the application of the firm for technical evaluation may not be considered			
	1	737	Amlodipine Tablets IP 5mg		May not be considered
	2	94	Ciprofloxacin Tablets IP 500 mg		May not be considered
	3	1629	Fluconazole Tablets IP 200mg		May not be considered
	4	743	Furazolidone Suspension IP 25mg/5ml,60ml		May not be considered
68	SAINTLIFE PHARMACEUTICALS LIMITED	Technical Evaluation Remarks by Committee of DCA: All the firm applied products 01-10 may be considered after obtaining the valid product mfg licenes (As the firm submitted previous license period licenses and also not mentioned clarity regarding previous licensed products retained in the license retention certificate)			
	1	737	Amlodipine Tablets IP 5mg	submitted product license pg no 14 dt: 18-07-2017 May be considered after obtaining valid product license	May not be considered
	2	37	Atenolol Tablets IP 50mg	submitted product license pg no 16 dt: 23-10-2017 May be considered after obtaining valid product license	May not be considered
	3	412375	Dextromethorphan oral Syrup 60 ml	submitted product license pg no 10 dt: 23-01-2018 May be considered after obtaining valid product license	May not be considered
	4	1137	Domperidone Tablets IP 10 mg	The firm submitted product license for uncoated tablets and the license dt: 18/03/2024 pg.13 May be considered after obtaining valid product mfg license	May not be considered
	5	1629	Fluconazole Tablets IP 200mg	submitted product license pg no 17 dt: 23-01-2018 May be considered after obtaining valid product license	May not be considered
	6	299	Glibenclamide Tablet 5 mg	submitted product license pg no 15 dt: 14-02-2018 May be considered after obtaining valid product license	May not be considered
	7	2344	Methyl Prednisolone IP 8mg Tablet	submitted product license dt: 01-12-2017 May be considered after obtaining valid product license	May not be considered
	8	1880	Metoprolol Succinate Tablets IP 25 mg	submitted product license for mouth dissdvng tablets and the license dt: 12-09-2017 pg 32 May be considered after obtaining valid product license with tender specification	May not be considered
	9	497	Nifedipine Capsules IP 10mg	submitted product license pg no 15 dt: 14-02-2018 May be considered after obtaining valid product license	May not be considered
	10	2429	Spironolactone Tablets IP 50 mg	submitted product license pg no 12 dt: 25-10-2017 May be considered after obtaining valid product license	May not be considered
69	SAM KEM PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: The firm is blacklisted issued in the state of Jammu & Kashmir vide Order No. 66-JKMSCL of 2025 dt: 21-08-2025 for a period of 2 years from the date of issue. Hence the firm may not be considered			

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	1	1123	Cetirizine Hcl Tablets IP 10mg		May not be considered
	2	94	Ciprofloxacin Tablets IP 500 mg		May not be considered
	3	1137	Domperidone Tablets IP 10 mg		May not be considered
	4	1629	Fluconazole Tablets IP 200mg		May not be considered
	5	299	Glibenclamide Tablet 5 mg		May not be considered
	6	574	Pyridoxine Hcl Tablets IP 5 mg		May not be considered
	7	140224086	Tab.Methyl Phenidate Hydrochloride 18mg		May not be considered
70	SAMARTH LIFE SCIENCES PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: The firm/application had submitted loan license no. 12P-MB-LL-00156 in Form-28A, Hence as the tender conditions the application may not be considered			
	1	140224136	Cardioplegia Solution 20ml inj		May not be considered
	2	209	Dopamine Hcl Injection IP 200mg in 5ml vial and ampoule		May not be considered
	3	608	Iron Sucrose Injection BP 100 mg / 5ml Ampoule/Vial		May not be considered
	4	140224042	Inj Methyl Prednisolone 40mg/ml,2m1 Amp		May not be considered
	5	1310	Methyl Prednesolone Sodium Succinate Injection USP 500 mg		May not be considered
71	SEEKO BIOTICS	Technical Evaluation Remarks by Committee of DCA: S No 8, 12 may be considered after submission of valid approval. Products S No 1, 2, 3, 4, 5, 6, 7, 9, 10, 11, 13 & 14 - May be considered			
	1	737	Amlodipine Tablets IP 5mg		May be considered
	2	6	Amoxicillin Capsules IP 250 mg		May be considered
	3	37	Atenolol Tablets IP 50mg		May be considered
	4	58	Bisacodyl Tablets IP 5 mg(Enteric Coated)		May be considered
	5	1621	Cefixime Dispersible Tablets USP 100 mg		May be considered
	6	1123	Cetirizine Hcl Tablets IP 10mg		May be considered
	7	94	Ciprofloxacin Tablets IP 500 mg		May be considered
	8	1137	Domperidone Tablets IP 10 mg	The firm submitted uncoated tablet approval at pg no 8 s.no.77 May be considered after submission approval	May not be considered
	9	1629	Fluconazole Tablets IP 200mg		May be considered
	10	299	Glibenclamide Tablet 5 mg		May be considered
	11	2344	Methyl Prednisolone IP 8mg Tablet		May be considered
	12	1880	Metoprolol Succinate Tablets IP 25 mg		May not be considered
	13	140224059	Tab.Racecadotril 100mg		May be considered
	14	2440	Zinc Sulphate Dispersible Tablet10mg		May be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
72	SIGNATURE PHYTOCHEMICAL INDUSTRIES	Technical Evaluation Remarks by Committee of DCA: May be considered for 1product at S No 2 May be considered for remaining 3 products at S No 1, 3, 4 after submission of valid product approval			
	1	6	Amoxicillin Capsules IP 250 mg	Not submitted valid product approval	May not be considered
	2	1341	Amoxycillin 250mg +125mg Clavulanic Acid Tablets		May be considered
	3	1621	Cefixime Dispersible Tablets USP 100 mg	Not submitted valid product approval	May not be considered
	4	1629	Fluconazole Tablets IP 200mg	Not submitted valid product approval	May not be considered
73	srinija parenterals	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for quoted items			
	1	198	Diclofenac Sodium Injection IP25 mg / ml in 3ml ampoule		May be considered
	2	209	Dopamine Hcl Injection IP 200mg in 5ml vial and ampoule		May be considered
74	STALLION LABORATORIES PVT LTD	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for all products except item code:1629			
	1	737	Amlodipine Tablets IP 5mg		May be considered
	2	37	Atenolol Tablets IP 50mg		May be considered
	3	1453	B Complex therapeutic (NFI III)		May be considered
	4	94	Ciprofloxacin Tablets IP 500 mg		May be considered
	5	1137	Domperidone Tablets IP 10 mg		May be considered
	6	1629	Fluconazole Tablets IP 200mg	Submitted product approval valid upto 23-01-2023 for Export only	May not be considered
	7	299	Glibenclamide Tablet 5 mg		May be considered
	8	4231	Hysocine butyl bromide Tablet 10mg		May be considered
75	STANDARD PHARMACEUTICALS LTD	Technical Evaluation Remarks by Committee of DCA: The applied 02 items may be considered after obtaining valid product mfg license			
	1	737	Amlodipine Tablets IP 5mg	Submitted product mfg license dt: 19-11-2008 pg no.10 May be considered after obtaining valid product license	May not be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	2	1341	Amoxycillin 250mg +125mg Clavulanic Acid Tablets	Submitted product mfg license dt: 04-03-2021 pg no.11 May be considered after obtaining valid product license	May not be considered
76	STRIDE ORGANICS PVT LTD	Technical Evaluation Remarks by Committee of DCA: The products S No 1, 3, 4, 5, 6, 7, 10, 14, 17, 18 & 19 - May be considered The products S No 2, 8, 9, 11, 12, 13, 15, 16, 20 - May be considered after submission of valid product licenses			
	1	737	Amlodipine Tablets IP 5mg		May be considered
	2	6	Amoxicillin Capsules IP 250 mg	Not submitted valid product license May be considered after obtaining valid product license	May not be considered
	3	1341	Amoxycillin 250mg +125mg Clavulanic Acid Tablets		May be considered
	4	37	Atenolol Tablets IP 50mg		May be considered
	5	1453	B Complex therapeutic (NFI III)		May be considered
	6	1621	Cefixime Dispersible Tablets USP 100 mg		May be considered
	7	94	Ciprofloxacin Tablets IP 500 mg		May be considered
	8	1137	Domperidone Tablets IP 10 mg	The firm submitted valid product license for uncoated tablet pg no.1 May be considered after obtaining valid product license with required specification	May not be considered
	9	2088	Febuxostat Tab 40mg	Not submitted valid product license May be considered after submission of valid product license	May not be considered
	10	1629	Fluconazole Tablets IP 200mg		May be considered
	11	299	Glibenclamide Tablet 5 mg	Not submitted valid product license May be considered after submission of valid product license	May not be considered
	12	1630	Griseofulvin Tablets IP 250 mg	Not submitted valid product license May be considered after submission of valid product license	May not be considered
	13	4231	Hysocine butyl bromide Tablet 10mg	Not submitted valid product license May be considered after submission of valid product license	May not be considered
	14	1637	Lactulose Solution 3.325gm/5ml in 100ml bottle		May be considered
	15	1880	Metoprolol Succinate Tablets IP 25 mg	Not submitted valid product license May be considered after submission of valid product license with required specification	May not be considered
	16	2351	Naproxen Sodium Tablet 500mg	Not submitted valid product license May be considered after submission of valid product license	May not be considered
	17	574	Pyridoxine Hcl Tablets IP 5 mg		May be considered
	18	2414	S. Metoprolol PR Tablet 25mg		May be considered
	19	1370	Vitamin A Paediatric retinol solution 100000 IU per ml		May be considered
	20	2440	Zinc Sulphate Dispersible Tablet10mg	Not submitted valid product license May be considered after submission of valid product license	May not be considered
77	SWISS PARENTERALS PVT. LTD.	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for quoted items			

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	1	53	Bupivacaine Hcl Injection IP 0.5 Percentage , in 20ml vial		May be considered
	2	2245	Clindamycin Injection 150 mg/ml in 2ml ampoule		May be considered
	3	209	Dopamine Hcl Injection IP 200mg in 5ml vial and ampoule		May be considered
	4	422084.01	Ferric Carboxy Maltose Injection 500mg in 10ml vial		May be considered
	5	608	Iron Sucrose Injection BP 100 mg / 5ml Ampoule/Vial		May be considered
	6	1310	Methyl Prednesolone Sodium Succinate Injection USP 500 mg		May be considered
78	Syndicate Pharma	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for quoted items			
	1	412375	Dextromethorphan oral Syrup 60 ml		May be considered
	2	743	Furazolidone Suspension IP 25mg/5ml,60ml		May be considered
79	TAKEDA BIOPHARMACEUTICALS INDIA PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: The applied item may be considered after submission of valid NCC from CDSCO as the import license & Registration certificates are issued by the CDSCO			
	1	1367	Human Albumin Solution I.P. 20% in bottle or bag	The firm submitted valid Registration certificate in Form-41 & valid import license in Form-10 (pg :32-52)	May be considered
80	TANMED PHARMA INDIA PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: The firm may be considered after submission of valid product approvals			
	1	2091	Flupirtine Maleate Capsules 100mg	Not submitted valid product approval	May not be considered
	2	140224130	Tab Atamoxetin 10 mg	Not submitted valid product approval	May not be considered
81	THE SWASTIKPHARMACEUTICALS	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for quoted items			
	1	73	Benzyl Benzoate application IP 25%w/w, 450ml bottle		May be considered
	2	1637	Lactulose Solution 3.325gm/5ml in 100ml bottle		May be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
82	Unicure India Pvt. Ltd.	Technical Evaluation Remarks by Committee of DCA: All the applied items S No 1 - 25 may be considered after obtaining valid product mfg licenses with required specifications your firm was Blacklisted by Assam Medical Services Corporation, Hence your are requested to submit further Clarification/Explanation on this order.			
	1	737	Amlodipine Tablets IP 5mg	Submitted product mfg license dt:02-02-17 of UP unit pg.18 May be considered after submission of valid product mfg license	May not be considered
	2	37	Atenolol Tablets IP 50mg	Submitted product mfg license dt:02-02-17 of UP unit pg.21 May be considered after submission of valid product mfg license	May not be considered
	3	1453	B Complex therapeutic (NFI III)	Submitted product mfg license dt:02-02-17 of UP unit pg.24 May be considered after submission of valid product mfg license	May not be considered
	4	73	Benzyl Benzoate application IP 25%w/w, 450ml bottole	Submitted product mfg license dt:02-02-17 of UP unit pg.17 May be considered after submission of valid product mfg license	May not be considered
	5	58	Bisacodyl Tablets IP 5 mg(Enteric Coated)	Submitted product mfg license dt:02-02-17 of UP unit pg.26 May be considered after submission of valid product mfg license	May not be considered
	6	1621	Cefixime Dispersible Tablets USP 100 mg	Submitted product mfg license dt:02-02-17 of UP unit pg.22 May be considered after submission of valid product mfg license	May not be considered
	7	2236	Cefixime Oral Suspension 25mg/ml, 10ml Bottle	Not submitted valid product license with required strength pg.25 May be considered after submission of valid product license	May not be considered
	8	1123	Cetirizine Hcl Tablets IP 10mg	Submitted product mfg license dt:02-02-17 of UP unit pg.23 May be considered after submission of valid product mfg license	May not be considered
	9	94	Ciprofloxacin Tablets IP 500 mg	Submitted product mfg license dt:02-02-17 of UP unit pg.10 May be considered after submission of valid product mfg license	May not be considered
	10	1137	Domperidone Tablets IP 10 mg	The firm submitted product mfg license for uncoated tablet and the license dt.02-02-2017 UP unit pg.11 May be considered after submission of valid product mfg license with required specification	May not be considered
	11	2088	Febuxostat Tab 40mg	The firm submitted product mfg license dt.21.01.2016 of Uttarakhand unit pg.35 May be considered after submission of valid product mfg license	May not be considered
	12	1629	Fluconazole Tablets IP 200mg	The firm submitted product mfg license dt.02.02.2017 for UP unit pg.12 May be considered after submission of valid product mfg license	May not be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	13	743	Furazolidone Suspension IP 25mg/5ml,60ml	The firm submitted product mfg license dt. 02-02-2017 for UP unit pg.14 May be considered after submission of valid product mfg license	May not be considered
	14	264.01	Furazolidone Tablets IP 100 mg	The firm submitted product mfg license for Dispersible Tablets and the license dt. 02-02-2017 for UP unit pg.12 May be considered after submission of valid product mfg license with required specification	May not be considered
	15	299.01	Glibenclamide Tablet 2.5 mg	The firm submitted product mfg license dt. 02-02-2017 of UP unit pg.19 May be considered after submission of valid product mfg license	May not be considered
	16	299	Glibenclamide Tablet 5 mg		May not be considered
	17	4231	Hysocine butyl bromide Tablet 10mg	The firm submitted product mfg license dt.02-02-17 of UP unit pg.20 May be considered after submission of valid product mfg license	May not be considered
	18	1637	Lactulose Solution 3.325gm/5ml in 100ml bottle	The firm submitted product mfg license dt. 02-02-17 of UP unit pg.14 May be considered after submission of valid product mfg license	May not be considered
	19	2344	Methyl Prednisolone IP 8mg Tablet	The firm submitted product mfg license dt. 21-11-13 of Uttarakhand unit pg.34 May be considered after submission of valid product mfg license	May not be considered
	20	1880	Metoprolol Succinate Tablets IP 25 mg	The firm submitted product license for Extended Release Tablets and the license dt.21-01-2016 Uttarakhand unit pg.32 May be considered after submission of valid product license with required specification	May not be considered
	21	2351	Naproxen Sodium Tablet 500mg	Submitted product mfg license dt. 02-02-17 of UP unit pg.13 May be considered after obtaining valid product mfg license	May not be considered
	22	2418	Sertaconazole Nitrate (Pessaries) 500 mg Tablet	Submitted product mfg license dt. 02-02-17 of UP unit pg.16 May be considered after obtaining valid product mfg license	May not be considered
	23	2429	Spironolactone Tablets IP 50 mg	The firm submitted product mfg license dt. 02-02-17 of UP unit pg.15 May be considered after submission of valid product mfg license	May not be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	24	1370	Vitamin A Paediatric retinol solution 100000 IU per ml	The firm submitted product mfg license dt. 02-02-17 of UP unit pg.27 May be considered after submission of valid product mfg license	May not be considered
	25	2441	Zolpidem tablets 10mg	The firm submitted product mfg license dt. 21-01-16 of UP unit pg.33 May be considered after submission of valid product mfg license	May not be considered
83	VANTIVE HEALTHCARE PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for quoted items			
	1	6630	CAPD (Continous Ambulatory Peritoneal Dialysis) Solution Set 1.5 Percentage , 2 Litres Bag With Integrated Asymmetric Y.Set		May be considered
	2	6631	CAPD (Continous Ambulatory Peritoneal Dialysis) Solution Set 2.5 Percentage , 2 Litres Bag With Integrated Asymmetric Y.Set		May be considered
84	vins bio products limited	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for quoted item			
	1	1681	Rabies Antiserum Injection Immunoglobulin, Equine 300 IU/ml		May be considered
85	VISION PARENTERAL PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: All the applied items S No 1 to 5 may be considered after submission of valid product mfg license by the firm			
	1	229	Dextrose Injection IP 5%w/v in 500ml BFS / FFS	Submitted product mfg license dt. 18-04-16 pg.6 s.no.3 May be considered after submission of valid product mfg license	May not be considered
	2	224	Dextrose with Sodium Chloride Injection 5% + 0.9% IP in 500ml IV BFS / FFS	Submitted product mfg license dt. 18-04-16 pg.6 s.no.4 May be considered after submission of valid product mfg license	May not be considered
	3	140224018	Inj Sodium chloride 0.9%100ml	Submitted product mfg license dt. 18-04-16 pg.6 s.no.2 May be considered after submission of valid product mfg license	May not be considered
	4	2119	Paracetamol Solution for Infusion (10mg/ml) in 100ml glass bottle i.e.1gm/100ml BFS/FFS	Submitted product mfg license dt. 18-04-16 pg.6 s.no.10 May be considered after submission of valid product mfg license	May not be considered
	5	640	Sodium Chloride Injection IP 0.9%in 500ml BFS / FFS	Submitted product mfg license dt. 18-04-16 pg.6 s.no.2 May be considered after submission of valid product mfg license	May not be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
86	Vivimed Labs Limited	Technical Evaluation Remarks by Committee of DCA: The items S No 2, 3 - May be considered The item S No 1 may be considered after submission of valid product mfg license			
	1	1656	Salbutamol Nebulising solution IP 10ml	Submitted product mfg license dt.01-04-14 of Uttarakhand unit pg.17 May be considered after submission of valid product mfg license	May not be considered
	2	2418	Sertaconazole Nitrate (Pessaries) 500 mg Tablet		May be considered
	3	412374	Sodium chloride nasal Drops 20ml		May be considered
87	WALLACE PHARMACEUTICALS PVT LTD	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for quoted item			
	1	1629	Fluconazole Tablets IP 200mg		May be considered
88	WILCURE REMEDIES PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for quoted items			
	1	6	Amoxicillin Capsules IP 250 mg		May be considered
	2	1621	Cefixime Dispersible Tablets USP 100 mg		May be considered
89	Windlas Biotech private limited	Technical Evaluation Remarks by Committee of DCA: The items S No 1, 2, 3, 4, 6 - May be considered The item S No 5 may be considered after submission of valid product license with required specification			
	1	737	Amlodipine Tablets IP 5mg		May be considered
	2	94	Ciprofloxacin Tablets IP 500 mg		May be considered
	3	1629	Fluconazole Tablets IP 200mg		May be considered
	4	1637	Lactulose Solution 3.325gm/5ml in 100ml bottle		May be considered
	5	1880	Metoprolol Succinate Tablets IP 25 mg	The firm submitted product license for Extended Release Tablets pg. 19 May be considered after submission of valid product license with required specification	May not be considered
	6	2429	Spironolactone Tablets IP 50 mg		May be considered
90	WOCKHARDT LTD	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for quoted items			

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	1	1631	Human Premixed Insulin Injection IP 30/70 in 10 ml vial		May be considered
	2	1634	Insulin Injection (Soluble) Human Injection IP 40 IU / ml in 10 ml vial		May be considered
91	ZEST PHARM	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for quoted items			
	1	6	Amoxicillin Capsules IP 250 mg		May be considered
	2	94	Ciprofloxacin Tablets IP 500 mg		May be considered
Note: All the bidders are here by requested to verify the Provisional Technical Evaluation Report and submit their supporting documents on or before 05.00PM on 05.01.2026 to the email id: tendersapmside@gmail.com with Subject : Reply to T No 178 (General Medicines) TEC Report					